应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
HALO 奥洛兹美医疗
交易中 03-02 11:16:27 EST
70.09
+0.56
+0.81%
最高
70.65
最低
68.02
成交量
56.95万
今开
68.33
昨收
69.53
日振幅
3.78%
总市值
82.42亿
流通市值
81.30亿
总股本
1.18亿
成交额
3,981万
换手率
0.49%
流通股本
1.16亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
“HALO交易”叠加Token调用量爆发,电力ETF(561560)份额连创历史新高
新浪基金 · 03-02 16:15
“HALO交易”叠加Token调用量爆发,电力ETF(561560)份额连创历史新高
HALO交易,火到A股!券商最新研判
券商中国 · 03-02 12:30
HALO交易,火到A股!券商最新研判
和讯投顾石琳:2026年华尔街最火的HALO交易是什么?
中金财经 · 03-02 10:52
和讯投顾石琳:2026年华尔街最火的HALO交易是什么?
【十大券商一周策略】A股如何开盘?3月涨价逻辑延续,资金避险带热“HALO交易”
券商中国 · 03-01 23:24
【十大券商一周策略】A股如何开盘?3月涨价逻辑延续,资金避险带热“HALO交易”
开年四连阳连创新高!Token出海+HALO交易加持,电力ETF配置正当时!
新浪基金 · 03-01 19:46
开年四连阳连创新高!Token出海+HALO交易加持,电力ETF配置正当时!
中信建投:“HALO”交易正席卷全球 聚焦高壁垒实体资产和AI基建增量环节
智通财经 · 03-01 19:24
中信建投:“HALO”交易正席卷全球 聚焦高壁垒实体资产和AI基建增量环节
申万宏源策略:也谈谈“HALO交易”
市场资讯 · 03-01 16:00
申万宏源策略:也谈谈“HALO交易”
华尔街忽然转向!大摩、高盛力荐HALO资产
格隆汇 · 02-28 13:30
华尔街忽然转向!大摩、高盛力荐HALO资产
高盛:投资者终于开始重视传统“资本密集型”企业
智通财经网 · 02-28 11:19
高盛:投资者终于开始重视传统“资本密集型”企业
全球资金拥抱“脱虚向实”主题! “HALO”光环之下,欧洲股市迈向13年来最长月度连涨
智通财经 · 02-27
全球资金拥抱“脱虚向实”主题! “HALO”光环之下,欧洲股市迈向13年来最长月度连涨
从软件泡沫到实体王者:华尔街为什么突然迷上HALO?
美股研究社 · 02-26
从软件泡沫到实体王者:华尔街为什么突然迷上HALO?
“AI颠覆一切”席卷股票市场 何处是安全避风港? 高盛给出关键词:HALO
智通财经 · 02-24
“AI颠覆一切”席卷股票市场 何处是安全避风港? 高盛给出关键词:HALO
奥洛兹美医疗发布全年营收展望:预计达13.85亿至14亿美元
投资观察 · 02-18
奥洛兹美医疗发布全年营收展望:预计达13.85亿至14亿美元
奥洛兹美医疗公布2025财年创纪录营收14亿美元,并重申2026年强劲财务指引
美股速递 · 02-18
奥洛兹美医疗公布2025财年创纪录营收14亿美元,并重申2026年强劲财务指引
奥洛兹美医疗:预计到2026年底将有15个合作伙伴项目处于开发阶段;并签署三项或更多新型药物递送许可协议
美股速递 · 01-28
奥洛兹美医疗:预计到2026年底将有15个合作伙伴项目处于开发阶段;并签署三项或更多新型药物递送许可协议
奥洛兹美医疗与武田达成全球合作,共同开发并商业化基于Enhanze®技术的维多珠单抗
美股速递 · 01-08
奥洛兹美医疗与武田达成全球合作,共同开发并商业化基于Enhanze®技术的维多珠单抗
Skye Bioscience Inc.计划于2026年年中启动Nimacimab联合Enhanze技术治疗肥胖症的2B期临床试验
美股速递 · 01-05
Skye Bioscience Inc.计划于2026年年中启动Nimacimab联合Enhanze技术治疗肥胖症的2B期临床试验
奥洛兹美医疗与Skye Bioscience达成全球合作与许可协议,共同评估Nimacimab与Enhanze®复方制剂用于肥胖症治疗
美股速递 · 01-05
奥洛兹美医疗与Skye Bioscience达成全球合作与许可协议,共同评估Nimacimab与Enhanze®复方制剂用于肥胖症治疗
美国FDA批准将Rybrevant Faspro™ (Amivantamab和Hyaluronidase-Lpuj)与Enhanze®联用治疗晚期EGFR突变非小细胞肺癌
美股速递 · 2025-12-18
美国FDA批准将Rybrevant Faspro™ (Amivantamab和Hyaluronidase-Lpuj)与Enhanze®联用治疗晚期EGFR突变非小细胞肺癌
Merus Nv:Halozyme将有权获得Petosemtamab净销售额的低至中个位数的版税
美股速递 · 2025-11-17
Merus Nv:Halozyme将有权获得Petosemtamab净销售额的低至中个位数的版税
加载更多
公司概况
公司名称:
奥洛兹美医疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
Halozyme Therapeutics, Inc.成立于1998年,于2007年11月从内华达州重新注册成立于特拉华州,是一家生物制药公司,专注于开发可改善患者护理的创新疗法并将其商业化。该公司的研究以细胞外基质为中心,围绕细胞的结构网络在组织完整性、细胞信号传导、迁移和存活中起着至关重要的作用。凭借多年研究积累的广泛专业知识,Halozyme利用其对ECM的深刻科学理解,开发针对这一复杂且生物丰富的环境的新型治疗方法和药物递送技术,旨在推进下一代治疗解决方案。
发行价格:
--
{"stockData":{"symbol":"HALO","market":"US","secType":"STK","nameCN":"奥洛兹美医疗","latestPrice":70.09,"timestamp":1772468187078,"preClose":69.53,"halted":0,"volume":569469,"delay":0,"changeRate":0.008054077376671973,"floatShares":115999999,"shares":117597000,"eps":2.56,"marketStatus":"交易中","change":0.56,"latestTime":"03-02 11:16:27 EST","open":68.325,"high":70.65,"low":68.02,"amount":39809299.914000005,"amplitude":0.037825,"askPrice":70.15,"askSize":48,"bidPrice":70.09,"bidSize":30,"shortable":3,"etf":0,"ttmEps":2.56,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1772485200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1099285200000,"exchange":"NASDAQ","adjPreClose":69.53,"preHourTrading":{"tag":"盘前","latestPrice":68.48,"preClose":69.53,"latestTime":"09:29 EST","volume":159,"amount":10992.83865,"timestamp":1772461774073,"change":-1.05,"changeRate":-0.015101,"amplitude":0.021142},"postHourTrading":{"tag":"盘后","latestPrice":69.53,"preClose":69.53,"latestTime":"19:21 EST","volume":56518,"amount":3929626.1729,"timestamp":1772238065267,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.405211,"impliedVol":0.4068,"impliedVolPercentile":0.5777},"requestUrl":"/m/hq/s/HALO","defaultTab":"news","newsList":[{"id":"2616838908","title":"“HALO交易”叠加Token调用量爆发,电力ETF(561560)份额连创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2616838908","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616838908?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:15","pubTimestamp":1772439300,"startTime":"0","endTime":"0","summary":"消息面上,除了“十五五”期间国家电网将推出服务新能源高质量发展十项举措带来的产业积极信号,近期全球流行的“HALO交易”与中国AI模型Token调用量首次超越美国的双重利好,或亦共同助推了电力板块配置价值的持续强化。Wind数据进一步显示,截至2026年2月27日,电力ETF三个交易日累计吸引1.97亿元资金净流入,助推基金规模与份额双双创下历史新高,分别突破11.39亿元和8.62亿份。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-02/doc-inhpqvan8195154.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","159611","561560","LU0053671581.USD","HALO"],"gpt_icon":0},{"id":"2616334729","title":"HALO交易,火到A股!券商最新研判","url":"https://stock-news.laohu8.com/highlight/detail?id=2616334729","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616334729?lang=zh_cn&edition=full","pubTime":"2026-03-02 12:30","pubTimestamp":1772425800,"startTime":"0","endTime":"0","summary":"节后复工,华尔街热议的“HALO交易”也在A股开启了一波映射演绎。申万宏源策略团队表示,HALO交易的集中演绎,表明市场开始集中推演AI时代产业组织形式可能发生的变化。所以,市场集中定价AI终局的潜在冲击时,错杀难免会出现。进一步来看,HALO策略的底层逻辑是AI将深刻重构产业和社会,本质是对科技板块的认可而非排斥,算力制造和电力能源作为AI产业高度依赖的基础设施,是HALO策略的优质方向。A股,集体公告!英伟达,重大发布!","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652256667&idx=2&sn=132aeb3daa373b46a7e2bfdebb44122f&chksm=85e5adba8eeb11aa98ed9d897657894bcf1ac4a31a9331379b509ceccb4a46737ffc2a8c5c10&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4139","159982","LU0053671581.USD","HALO","399300"],"gpt_icon":0},{"id":"2616806274","title":"和讯投顾石琳:2026年华尔街最火的HALO交易是什么?","url":"https://stock-news.laohu8.com/highlight/detail?id=2616806274","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616806274?lang=zh_cn&edition=full","pubTime":"2026-03-02 10:52","pubTimestamp":1772419931,"startTime":"0","endTime":"0","summary":"2026年华尔街最火的投资策略Halo,无需复杂公式,一分钟即可掌握其核心逻辑。Halo并非某只股票,而是一套应对AI颠覆风险的对冲策略,全称为\"重资产加低淘汰风险\"。其本质在于只配置不易被AI取代的硬资产,规避易被替代的轻资产。此类资产属于刚需领域,技术迭代缓慢,即便AI技术再先进也难以替代。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangceping/20260302/32036987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"2616876212","title":"【十大券商一周策略】A股如何开盘?3月涨价逻辑延续,资金避险带热“HALO交易”","url":"https://stock-news.laohu8.com/highlight/detail?id=2616876212","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616876212?lang=zh_cn&edition=full","pubTime":"2026-03-01 23:24","pubTimestamp":1772378640,"startTime":"0","endTime":"0","summary":"【十大券商一周策略】A股如何开盘?3月涨价逻辑延续,资金避险带热“HALO交易”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzA3NjM5MjIwOQ==&mid=2652256605&idx=2&sn=da503458562896ac59136eea12575650&chksm=853e4bceaf7160fcf84cc0411a4739eeff4ef5e3a7fea79ce5cc91bbb4dbb8bcb4a8f8806365&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["159982","LU0053671581.USD","HALO","399300","BK4139"],"gpt_icon":0},{"id":"2616482424","title":"开年四连阳连创新高!Token出海+HALO交易加持,电力ETF配置正当时!","url":"https://stock-news.laohu8.com/highlight/detail?id=2616482424","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616482424?lang=zh_cn&edition=full","pubTime":"2026-03-01 19:46","pubTimestamp":1772365560,"startTime":"0","endTime":"0","summary":"周五,电力板块狂掀涨停潮,多只大牛股连板!其中,豫能控股七连板,赣能股份三连板,华银电力两连板,协鑫能科、涪陵电力、金开新能首板涨停,甘肃能源、乐山电力、永泰能源、建投能源等多股大涨超5%。 热门ETF方面,电力ETF华宝场内再涨2.64%连创上市新高,开年以来日线斩获四连阳,单日放量成交超1亿元。 综合市场信息来看,AI热潮下,电力板块投资迎来新的双重硬核利好:一是Token调用量背后的电力出海逻辑;二是HALO交易加持。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-01/doc-inhpnwmf5293604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","159611","561560","LU0053671581.USD","HALO"],"gpt_icon":0},{"id":"2616249318","title":"中信建投:“HALO”交易正席卷全球 聚焦高壁垒实体资产和AI基建增量环节","url":"https://stock-news.laohu8.com/highlight/detail?id=2616249318","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616249318?lang=zh_cn&edition=full","pubTime":"2026-03-01 19:24","pubTimestamp":1772364242,"startTime":"0","endTime":"0","summary":"“HALO”交易正在席卷全球,实物资产板块迎来价值重估,聚焦高壁垒实体资产和AI基建增量环节。AI涨价主线延续,“HALO”交易深化英伟达财务表现强劲,再次印证全球AI算力需求的强劲扩张,算力基建仍是核心主线,配套环节同步受益。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0276","HALO","LU0053671581.USD","601066","BK4139"],"gpt_icon":0},{"id":"2616829253","title":"申万宏源策略:也谈谈“HALO交易”","url":"https://stock-news.laohu8.com/highlight/detail?id=2616829253","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616829253?lang=zh_cn&edition=full","pubTime":"2026-03-01 16:00","pubTimestamp":1772352000,"startTime":"0","endTime":"0","summary":" 一、也谈谈“HALO交易”:市场开始集中推演,AI时代产业组织形式可能发生的变化。可能被AI替代的行业 + 在AI时代壁垒弱化,超额利润可能压缩的行业 + 在AI时代可能无法继续胜出的科技龙头,长期预期正在重新锚定,估值中枢存在下行压力。 不易被替代的战略资源本就是时代资产:战略资源安全可控 + AI时代仍会“通胀”。这与“HALO交易”在A股的映射有关,也与美联储宽松预期扰动,A股科技叙事行情演绎相对充分有关。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-01/doc-inhpnmvs6188085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0028","BK0276","BK4139","BK0012","BK1564","BK1147","000166","HALO","LU0053671581.USD","BK0188","BK0183","06806"],"gpt_icon":0},{"id":"2614897411","title":"华尔街忽然转向!大摩、高盛力荐HALO资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2614897411","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614897411?lang=zh_cn&edition=full","pubTime":"2026-02-28 13:30","pubTimestamp":1772256633,"startTime":"0","endTime":"0","summary":"2月28日,AI引发的产业颠覆迫使投资人重新评估风险,具备“重资产、低淘汰率”特质的企业正成为资本避险新宠。高盛最新研报也进一步印证这一趋势,在利率攀升、地缘割裂与AI资本开支激增的三重压力下,市场正经历“稀缺性重定价”,有形生产能力成为稀缺资源。2月以来,电力板块强势崛起,核心驱动力正是HALO交易逻辑与AI带来的电力需求增长。而近日稀土、小金属等核心材料类HALO资产受供需关系与AI需求驱动,亦成为资金布局重点。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2026/02/28133056124874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["LU1244550577.SGD","LU2750360641.GBP","BK4550","LU2237443382.USD","LU1732799900.SGD","LU0251142724.SGD","LU1162221912.USD","LU2237443465.HKD","HALO","IE0004091025.USD","LU0742534661.SGD","LU1791807156.HKD","LU2347655156.SGD","LU2271345857.HKD","IE00BKVL7J92.USD","IE0034235188.USD","LU1989772923.USD","BK4581","LU0048573561.USD","LU0912757837.SGD","BK4534","IE00B19Z3581.USD","GSX","LU1720051017.SGD","LU1791710582.SGD","LU2471134796.USD","LU1868837300.USD","LU2023251221.USD","IE0002270589.USD","BK4588","LU2028103732.USD","LU1868836591.USD","IE0004086264.USD","LU0096364046.USD","LU2471134879.HKD","LU1732800096.USD","LU1894683264.USD","LU0251131958.USD","LU0234570918.USD","LU2111349929.HKD","LU0106261372.USD","LU0314104364.USD","LU0528227936.USD","LU0106831901.USD","IE00BSNM7G36.USD","LU2471134952.CNY","LU2237438978.USD","BK4552","LU0795875169.SGD","LU2237443895.HKD"],"gpt_icon":0},{"id":"2614894318","title":"高盛:投资者终于开始重视传统“资本密集型”企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2614894318","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614894318?lang=zh_cn&edition=full","pubTime":"2026-02-28 11:19","pubTimestamp":1772248769,"startTime":"0","endTime":"0","summary":"盛策略师Chris Hussey强调,投资者正在给予传统资本密集型企业更高的估值,且向供应链上下游及更广泛的经济领域延伸。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260228/20260228112209_57746.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260228/20260228112209_57746.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408605.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU1668664300.SGD","LU0251142724.SGD","LU2237443382.USD","VGT","LU0106831901.USD","IE00B19Z3B42.SGD","IE00BFXG1179.USD","LU0742534661.SGD","LU1894683264.USD","BK4504","BK4127","LU0048573561.USD","LU2471134523.USD","LU0345770308.USD","LU2237443622.USD","LU2237443978.SGD","LU1791807156.HKD","BK4585","LU2237443465.HKD","IE0004091025.USD","LU0096364046.USD","LU1894683348.USD","LU1868836757.USD","IE00B19Z3581.USD","BK4550","IE00BSNM7G36.USD","LU2471134879.HKD","LU1804176565.USD","LU2750360641.GBP","LU1868837136.USD","IE0004086264.USD","LU2471134952.CNY","LU2471134796.USD","BK4533","BK4552","LU2750360997.AUD","LU1868836914.USD","LU1868836591.USD","GSX","LU2237443549.SGD","BK4588","IE0002270589.USD","BK4516","LU1868837300.USD","LU0053671581.USD","IE0034235188.USD","LU2237438978.USD","LU0251131958.USD","HALO","LU0345770993.USD"],"gpt_icon":0},{"id":"2614831387","title":"全球资金拥抱“脱虚向实”主题! “HALO”光环之下,欧洲股市迈向13年来最长月度连涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2614831387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614831387?lang=zh_cn&edition=full","pubTime":"2026-02-27 18:13","pubTimestamp":1772187206,"startTime":"0","endTime":"0","summary":"如上图所显示的那样,欧洲股市非常有望创下自2013年以来最长连涨纪录——斯托克欧洲600指数有望录得连续八个月上涨。此外,整体偏正面的积极财报季进一步提振了市场对欧洲股市的看涨情绪。此外,欧洲企业宣布股票回购的规模也创下纪录。根据美国银行策略师援引EPFR Global的统计数据,截至周三当周,欧洲股票型基金获得高达32亿美元资金流入,连续四周录得净流入。今年迄今,投资者们已向欧洲市场的股票基金投入180亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408243.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","HALO","VT","LU0053671581.USD","BK4588","BK4139"],"gpt_icon":0},{"id":"2614029170","title":"从软件泡沫到实体王者:华尔街为什么突然迷上HALO?","url":"https://stock-news.laohu8.com/highlight/detail?id=2614029170","media":"美股研究社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614029170?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:32","pubTimestamp":1772109120,"startTime":"0","endTime":"0","summary":"HALO 不是逆 AI,而是 AI 时代的物理底座。HALO为何预示新时代的到来——从“软件至上”到“实体稀缺”要理解 HALO 的崛起,必须首先复盘过去十年美股的底层逻辑。尤为值得注意的是 Apple Inc. 被纳入 HALO 范畴。不被AI颠覆的公司,正在被AI放大——从防御资产到进攻资产更值得关注的是,HALO 企业并非“防御型老资产”。市场曾误以为重资产意味着低效率、低增长,但在 AI 时代,它们正在成为 AI 赋能的直接受益者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzI4Mzc0ODQxOQ==&mid=2247791605&idx=1&sn=dfd7ea0df1b7594c811ccc7cf16b0df9&chksm=ea91ef3c42227dcd8bf2ec456ffe5dbfebeec336ce6f82c0e0c8964d07dc349cf90cb8b75378&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["BK4139","BK4585","BK4588","LU0053671581.USD","VGT","HALO"],"gpt_icon":0},{"id":"2613715702","title":"“AI颠覆一切”席卷股票市场 何处是安全避风港? 高盛给出关键词:HALO","url":"https://stock-news.laohu8.com/highlight/detail?id=2613715702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613715702?lang=zh_cn&edition=full","pubTime":"2026-02-24 20:00","pubTimestamp":1771934418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,华尔街金融巨头高盛集团策略师称,拥有有形性质生产资产的重资产型公司股价正在显著跑赢全球股票市场,主要因为包括对冲基金与散户们在内的全球投资者们积极寻求能够躲避“人工智能颠覆一切”抛售风暴的安全避风港之际,默契将投资目光转向那些重资产密集型的HALO类股票标的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4516","BK4588","LU0251131958.USD","IE00B19Z3B42.SGD","LU2471134796.USD","LU1868836591.USD","LU2471134952.CNY","BK4504","LU2237443465.HKD","LU0061475181.USD","LU2237443978.SGD","IE0034235188.USD","BK4533","LU2237443549.SGD","LU1804176565.USD","LU0096364046.USD","LU1868836914.USD","BK4585","IE0004091025.USD","LU1668664300.SGD","LU1791807156.HKD","GSX","LU0345770993.USD","BK4127","LU0251142724.SGD","LU0106831901.USD","LU1868837136.USD","LU1894683264.USD","LU2237443622.USD","BK4550","IE0002270589.USD","LU2237443382.USD","IE00B19Z3581.USD","LU2265009873.SGD","LU2750360997.AUD","HALO","LU0345770308.USD","LU1894683348.USD","LU0048573561.USD","LU2237438978.USD","LU2237443895.HKD","LU1868836757.USD","LU2750360641.GBP","BK4552","IE0004086264.USD","IE00BSNM7G36.USD","LU1868837300.USD","LU0742534661.SGD","IE00BFXG1179.USD","BK4139"],"gpt_icon":0},{"id":"1117593428","title":"奥洛兹美医疗发布全年营收展望:预计达13.85亿至14亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1117593428","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117593428?lang=zh_cn&edition=full","pubTime":"2026-02-18 08:04","pubTimestamp":1771373095,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公布了其新财年的营收预期,公司预计全年总收入将在13.85亿美元至14亿美元之间。这一展望反映了公司对其核心业务增长势头的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HALO","LU0053671581.USD"],"gpt_icon":0},{"id":"1111510374","title":"奥洛兹美医疗公布2025财年创纪录营收14亿美元,并重申2026年强劲财务指引","url":"https://stock-news.laohu8.com/highlight/detail?id=1111510374","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111510374?lang=zh_cn&edition=full","pubTime":"2026-02-18 05:02","pubTimestamp":1771362164,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗公布了其2025财年的业绩,全年营收达到创纪录的14亿美元,彰显了公司强劲的增长势头。同时,公司管理层重申了对2026财年的积极财务展望,显示出对未来发展的坚定信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1169384348","title":"奥洛兹美医疗:预计到2026年底将有15个合作伙伴项目处于开发阶段;并签署三项或更多新型药物递送许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1169384348","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169384348?lang=zh_cn&edition=full","pubTime":"2026-01-28 19:33","pubTimestamp":1769599991,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗近日公布了其未来几年的战略发展目标。公司预计,到2026年底,其合作伙伴项目数量将达到15个,这些项目届时将处于不同的开发阶段。此外,该公司还计划签署至少三项新的药物递送技术许可协议,以进一步拓展其业务版图。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","HALO"],"gpt_icon":0},{"id":"1100522345","title":"奥洛兹美医疗与武田达成全球合作,共同开发并商业化基于Enhanze®技术的维多珠单抗","url":"https://stock-news.laohu8.com/highlight/detail?id=1100522345","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100522345?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:03","pubTimestamp":1767877380,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗(Halozyme Therapeutics)宣布,已与武田制药(Takeda)签署了一项全球合作与许可协议。根据该协议,双方将携手利用奥洛兹美的Enhanze®药物递送技术,共同开发并商业化其药物维多珠单抗(Vedolizumab)。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1158508067","title":"Skye Bioscience Inc.计划于2026年年中启动Nimacimab联合Enhanze技术治疗肥胖症的2B期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1158508067","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158508067?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:03","pubTimestamp":1767614583,"startTime":"0","endTime":"0","summary":"Skye Bioscience Inc.近日公布其研发战略,计划在2026年中期正式启动一项针对肥胖症治疗的2B期临床试验。该试验将重点评估其核心候选药物Nimacimab与奥洛兹美医疗(Halozyme Therapeutics)专有的Enhanze药物递送技术联合应用的疗效与安全性。\n这一临床进展标志着Skye在代谢疾病治疗领域迈出了关键一步。Nimacimab作为一种创新疗法,结合Enhanze技术旨在增强药物递送效率,有望为肥胖患者提供新的治疗选择。公司预计该试验将为后续临床开发提供重要数据支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","LU0053671581.USD","HALO","BK4139"],"gpt_icon":0},{"id":"1162485011","title":"奥洛兹美医疗与Skye Bioscience达成全球合作与许可协议,共同评估Nimacimab与Enhanze®复方制剂用于肥胖症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1162485011","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162485011?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:02","pubTimestamp":1767614523,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗与Skye Bioscience公司宣布,双方已签署一项全球性的合作与许可协议。该协议的核心内容是,将共同评估Nimacimab与奥洛兹美医疗的Enhanze®药物递送技术共同配制的复方制剂,用于治疗肥胖症的潜力。此次合作旨在结合两家公司的专长,探索这一创新疗法在代谢疾病领域的应用前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SKYE","HALO","LU0053671581.USD","BK4139"],"gpt_icon":0},{"id":"1131503437","title":"美国FDA批准将Rybrevant Faspro™ (Amivantamab和Hyaluronidase-Lpuj)与Enhanze®联用治疗晚期EGFR突变非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1131503437","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131503437?lang=zh_cn&edition=full","pubTime":"2025-12-18 20:02","pubTimestamp":1766059323,"startTime":"0","endTime":"0","summary":"美国FDA批准将Rybrevant Faspro™ (Amivantamab和Hyaluronidase-Lpuj)与Enhanze®联用治疗晚期EGFR突变非小细胞肺癌","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HALO","BK4139","LU0053671581.USD"],"gpt_icon":0},{"id":"1185472202","title":"Merus Nv:Halozyme将有权获得Petosemtamab净销售额的低至中个位数的版税","url":"https://stock-news.laohu8.com/highlight/detail?id=1185472202","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1185472202?lang=zh_cn&edition=full","pubTime":"2025-11-17 20:04","pubTimestamp":1763381051,"startTime":"0","endTime":"0","summary":"Merus Nv:Halozyme将有权获得Petosemtamab净销售额的低至中个位数的版税","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","BK4139","HALO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.halozyme.com","stockEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0453},{"period":"3month","weight":-0.0262},{"period":"6month","weight":-0.0495},{"period":"1year","weight":0.205},{"period":"ytd","weight":0.0331}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Halozyme Therapeutics, Inc.成立于1998年,于2007年11月从内华达州重新注册成立于特拉华州,是一家生物制药公司,专注于开发可改善患者护理的创新疗法并将其商业化。该公司的研究以细胞外基质为中心,围绕细胞的结构网络在组织完整性、细胞信号传导、迁移和存活中起着至关重要的作用。凭借多年研究积累的广泛专业知识,Halozyme利用其对ECM的深刻科学理解,开发针对这一复杂且生物丰富的环境的新型治疗方法和药物递送技术,旨在推进下一代治疗解决方案。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.005218},{"month":2,"riseRate":0.590909,"avgChangeRate":0.022787},{"month":3,"riseRate":0.52381,"avgChangeRate":0.043178},{"month":4,"riseRate":0.590909,"avgChangeRate":-0.006442},{"month":5,"riseRate":0.545455,"avgChangeRate":0.005082},{"month":6,"riseRate":0.590909,"avgChangeRate":0.043711},{"month":7,"riseRate":0.636364,"avgChangeRate":0.034998},{"month":8,"riseRate":0.5,"avgChangeRate":-0.00554},{"month":9,"riseRate":0.363636,"avgChangeRate":0.020207},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.027834},{"month":11,"riseRate":0.636364,"avgChangeRate":0.065813},{"month":12,"riseRate":0.545455,"avgChangeRate":0.110354}],"exchange":"NASDAQ","name":"奥洛兹美医疗","nameEN":"Halozyme Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥洛兹美医疗,HALO,奥洛兹美医疗股票,奥洛兹美医疗股票老虎,奥洛兹美医疗股票老虎国际,奥洛兹美医疗行情,奥洛兹美医疗股票行情,奥洛兹美医疗股价,奥洛兹美医疗股市,奥洛兹美医疗股票价格,奥洛兹美医疗股票交易,奥洛兹美医疗股票购买,奥洛兹美医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥洛兹美医疗(HALO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥洛兹美医疗(HALO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}